Insider Selling: Septerna (NASDAQ:SEPN) Insider Sells $219,250.00 in Stock

Septerna, Inc. (NASDAQ:SEPN) insider Samira Shaikhly sold 6,250 shares of Septerna stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $35.08, for a total value of $219,250.00. Following the sale, the insider owned 793 shares of the company’s stock, valued at approximately $27,818.44. This represents a 88.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Samira Shaikhly also recently made the following trade(s):

• On Monday, June 1st, Samira Shaikhly sold 5,935 shares of Septerna stock. The shares were sold at an average price of $28.93, for a total transaction of $171,699.55.
• On Tuesday, May 26th, Samira Shaikhly sold 11,798 shares of Septerna stock. The stock was sold at an average price of $30.06, for a total transaction of $354,647.88.

Septerna Price Performance

Shares of NASDAQ SEPN opened at $36.17 on Friday. The company has a market cap of $1.63 billion, a PE ratio of -44.65 and a beta of 2.39. Septerna, Inc. has a 12 month low of $9.96 and a 12 month high of $37.32. The company has a 50-day simple moving average of $27.84 and a 200-day simple moving average of $26.97.

Septerna (NASDAQ:SEPN) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.23. The business had revenue of $26.52 million during the quarter, compared to analyst estimates of $16.98 million. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. On average, analysts anticipate that Septerna, Inc. will post -1.57 EPS for the current year.

Hedge Funds Weigh In On Septerna

Hedge funds have recently made changes to their positions in the stock. Deutsche Bank AG increased its holdings in shares of Septerna by 5.3% during the 4th quarter. Deutsche Bank AG now owns 14,879 shares of the company’s stock worth $415,000 after buying an additional 744 shares during the last quarter. Global Retirement Partners LLC acquired a new position in Septerna in the fourth quarter valued at $35,000. JPMorgan Chase & Co. boosted its holdings in Septerna by 15.0% in the second quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock valued at $107,000 after acquiring an additional 1,315 shares during the last quarter. PharVision Advisers LLC boosted its holdings in Septerna by 17.5% in the third quarter. PharVision Advisers LLC now owns 11,932 shares of the company’s stock valued at $224,000 after acquiring an additional 1,780 shares during the last quarter. Finally, Nuveen LLC grew its position in Septerna by 7.7% during the fourth quarter. Nuveen LLC now owns 25,798 shares of the company’s stock valued at $719,000 after acquiring an additional 1,837 shares during the period.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Raymond James Financial increased their price target on Septerna from $47.00 to $53.00 and gave the stock a “strong-buy” rating in a research note on Monday, June 8th. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Septerna in a research note on Wednesday, May 13th. Stifel Nicolaus assumed coverage on Septerna in a research report on Friday, May 1st. They set a “buy” rating and a $43.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a research report on Tuesday, April 21st. Finally, Wells Fargo & Company raised their price target on Septerna from $28.00 to $48.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 3rd. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $45.78.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.